Functional Selectivity of Hallucinogenic Phenethylamine and Phenylisopropylamine Derivatives at Human 5-Hydroxytryptamine (5-HT)2A and 5-HT2C Receptors

  title={Functional Selectivity of Hallucinogenic Phenethylamine and Phenylisopropylamine Derivatives at Human 5-Hydroxytryptamine (5-HT)2A and 5-HT2C Receptors},
  author={Pablo R. Moya and Kelly A Berg and Manuel A. Gutiérrez-Hernandez and Patricio S{\'a}ez-Briones and Miguel Reyes-Parada and Bruce K. Cassels and William P Clarke},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  pages={1054 - 1061}
  • P. MoyaK. Berg W. Clarke
  • Published 1 June 2007
  • Biology, Chemistry
  • Journal of Pharmacology and Experimental Therapeutics
2,5-Dimethoxy-4-substituted phenylisopropylamines and phenethylamines are 5-hydroxytryptamine (serotonin) (5-HT)2A/2C agonists. The former are partial to full agonists, whereas the latter are partial to weak agonists. However, most data come from studies analyzing phospholipase C (PLC)-mediated responses, although additional effectors [e.g., phospholipase A2 (PLA2)] are associated with these receptors. We compared two homologous series of phenylisopropylamines and phenethylamines measuring both… 

Figures and Tables from this paper

Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines

4-alkyloxy-substituted 2,5-dimethoxyamphetamines and Phenethylamines share some trends with the many other phenethylamine pharmacophore containing compounds, such as when increasing the size of the 4- substituent and increasing the lipophilicity, the affinities at the 5-HT2A/C subtype also increase, and only weak 5- HT2A or C subtype selectivities were achieved.

5-HT2 receptor binding, functional activity and selectivity in N-benzyltryptamines

Although some N-benzyltryptamines might be abuse-liable, others might represent new leads for the development of therapeutics for weight loss, erectile dysfunction, drug abuse, or schizophrenia.

Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens

S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models

In vitro and in vivo, the novel benzourea derivative, S32006 is a potent 5-HT2C receptor antagonist, and possesses antidepressant and anxiolytic properties in diverse rodent models.

Serotonin, But Not N-Methyltryptamines, Activates the Serotonin 2A Receptor Via a β-Arrestin2/Src/Akt Signaling Complex In Vivo

It is proposed that there is a bifurcation of 5-HT2AR signaling that is neurotransmitter and β-arrestin2 dependent and may significantly impact drug discovery efforts for the treatment of disorders wherein hallucinations are part of the etiology, such as schizophrenia, or manifest as side effects of treatment,such as depression.



Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, 5-HT2B and 5-HT2C receptors

The present study examined and compared the binding of 17 phenylisopropylamines at human 5- HT2A, 5-HT2B, and 5-Hat2C receptors and found a significant correlation between 5-ht2B receptor affinity and human hallucinogenic potency.

Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity.

The results suggest that these compounds (including the widely used 5- HT2 agonists DOB and DOI) are 5-HT1C/5-HT2 agents.

Differential phospholipase C activation by phenylalkylamine serotonin 5‐HT2A receptor agonists

The hypothesis that phenylisopropylamines have higher hallucinogenic potency than their phenethylamine analogues primarily because they have higher intrinsic activities at 5‐HT2A receptors is supported.

Multiple conformations of native and recombinant human 5-hydroxytryptamine(2a) receptors are labeled by agonists and discriminated by antagonists.

These results conform with the extended ternary complex model of receptor action that postulates the existence of partly activated receptor conformation(s) (R*) in equilibrium with the ground (R) and the activated G protein-coupled (R*G) conformations.

Serotonin 5-Hydroxytryptamine2A Receptor-Coupled Phospholipase C and Phospholipase A2 Signaling Pathways Have Different Receptor Reserves

The data support the hypothesis of agonist-directed trafficking in NIH3T3–5HT2A cells because structurally distinct ligands were able to induce preferential activation of the PLC or PLA2 signaling pathway and conclude that structurally different ligands can differentially regulate 5-HT 2A receptor signal transduction.

SB 242084, a Selective and Brain Penetrant 5-HT2C Receptor Antagonist

Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors

Results indicate that lisuride may possess hallucinogenic activity, although the psychopharmacological effects of l isuride appear to be different from the hallucinationsinogenic effects of LSD.

Differences in agonist-independent activity of 5-HT2A and 5-HT2C receptors revealed by heterologous expression

Data indicate that the 5- HT2A receptor has a much lower intrinsic ability to spontaneously adopt or maintain the active receptor conformation than does the closely related 5-HT2C receptor.

Behavioral Evidence for Interactions between a Hallucinogenic Drug and Group II Metabotropic Glutamate Receptors

1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist.

The title compound 5 and its alpha-desmethyl congener 6 appear to be the most potent of the so-called hallucinogenic amphetamine 5-HT agonists reported to date.